Publication

Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma

Veldman, J., Visser, L., Berg, A. V. D. & Diepstra, A., Jan-2020, In : CANCER TREATMENT REVIEWS. 82, 9 p., 101931.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma

    Final publisher's version, 7 MB, PDF document

    Request copy

DOI

Hodgkin lymphoma is a B cell derived malignancy characterized by a low number of tumor cells within an environment consisting of inflammatory cells. Recently, immune checkpoint blockade targeting the PD-1-PD-L1 axis has shown to be a great success in relapsed and refractory Hodgkin lymphoma patients. However, complete responses are scarce and median progression-free survival is limited to around 11-15 months. Efficiency of PD-1 blockade in HL might be dependent on CD4 + T cells, but also tumor associated macrophages (TAMs) and NK cells are implicated. The aim of this review is to highlight currently known prominent immune evasion strategies and discuss their possible contribution to primary or acquired resistance to immune checkpoint blockade in Hodgkin lymphoma. These include T cell dependent mechanisms such as shaping of the inflammatory infiltrate, lack of presentation of antigens and neoantigens and production of molecules involved in suppression of T cell functionality such as other immune checkpoints, indoleamine 2,3-dioxygenase and adenosine. Moreover, the role of NK cells and TAMs in efficient PD-1 blockade will be discussed. Targeting these mechanisms in parallel to PD-1 may potentially increase efficiency of PD-1 blockade therapy.

Original languageEnglish
Article number101931
Number of pages9
JournalCANCER TREATMENT REVIEWS
Volume82
Early online date11-Nov-2019
Publication statusPublished - Jan-2020

    Keywords

  • Hodgkin lymphoma, Immune checkpoint inhibitors, PD-1 inhibitors, Resistance mechanisms, Tumor immunology, Antigen presentation, REED-STERNBERG CELLS, EPSTEIN-BARR-VIRUS, HLA-CLASS-I, IMMUNOGLOBULIN GENE REARRANGEMENTS, COMPLEX CLASS-I, CD8(+) T-CELLS, PD-1 BLOCKADE, INDOLEAMINE 2,3-DIOXYGENASE, MUTATIONAL LANDSCAPE, ANALYSIS REVEALS

ID: 103278470